Resources Management Corp CT ADV Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Resources Management Corp CT ADV acquired a new stake in Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 234,682 shares of the biopharmaceutical company’s stock, valued at approximately $8,432,000. Pfizer comprises approximately 1.6% of Resources Management Corp CT ADV’s investment portfolio, making the stock its 20th biggest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Princeton Global Asset Management LLC increased its stake in Pfizer by 5.8% in the third quarter. Princeton Global Asset Management LLC now owns 29,127 shares of the biopharmaceutical company’s stock valued at $1,032,000 after purchasing an additional 1,591 shares in the last quarter. Keeley Teton Advisors LLC grew its holdings in shares of Pfizer by 1.6% in the 3rd quarter. Keeley Teton Advisors LLC now owns 42,764 shares of the biopharmaceutical company’s stock valued at $1,537,000 after buying an additional 685 shares during the period. Lockheed Martin Investment Management Co. increased its position in shares of Pfizer by 2.8% in the 3rd quarter. Lockheed Martin Investment Management Co. now owns 410,580 shares of the biopharmaceutical company’s stock valued at $14,752,000 after buying an additional 11,080 shares in the last quarter. IHT Wealth Management LLC increased its position in shares of Pfizer by 20.5% in the 3rd quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock valued at $2,595,000 after buying an additional 12,291 shares in the last quarter. Finally, Wealthsource Partners LLC increased its position in shares of Pfizer by 5.5% in the 3rd quarter. Wealthsource Partners LLC now owns 23,860 shares of the biopharmaceutical company’s stock valued at $857,000 after buying an additional 1,247 shares in the last quarter. Institutional investors and hedge funds own 70.25% of the company’s stock.

In other news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Several research analysts have weighed in on the company. Bank of America assumed coverage on Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price on the stock. Credit Suisse Group restated a “hold” rating and issued a $41.30 price target on shares of Pfizer in a report on Wednesday, November 6th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Nine equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $43.19.

NYSE PFE traded up $0.09 on Wednesday, reaching $38.14. The company had a trading volume of 13,532,890 shares, compared to its average volume of 23,171,512. The firm has a market capitalization of $213.17 billion, a price-to-earnings ratio of 12.71, a price-to-earnings-growth ratio of 3.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $44.99. The company’s fifty day moving average is $37.48 and its 200-day moving average is $38.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company’s revenue for the quarter was down 4.6% on a year-over-year basis. During the same quarter last year, the business posted $0.78 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were issued a dividend of $0.36 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.78%. Pfizer’s payout ratio is presently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.